Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer

British Journal of Cancer

Volumn 74, Issue 12, 1996, Pages 2008-2012

  Gabra, H ^a   Cameron, D A ^a   Lee, L E ^a   Mackay, J ^a   Leonard, R C F ^a   Anderson, E ^b   Anderson, T ^b   Chetty, U ^b   Dixon, M ^b   Hawkins, A ^b   Jack, W ^b   Kunkler, I ^b   Leonard, R ^b   Matheson, L ^b   Miller, W ^b  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Dose intensity; Doxorubicin; Metastasis; Survival; Toxicity

Indexed keywords

DOXORUBICIN; FLUOROURACIL;

ADULT; ADVANCED CANCER; ALOPECIA; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PUSTULOSIS PALMOPLANTARIS; SURVIVAL TIME; VOMITING;

EID: 8044260248     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.668     Document Type: Article

References (18)

1. GORDON CJ, VALDIVIESO M, MARTINO S, REDMAN BG, FLAHERTY L AND BAKER LH. (1990). Continuous intravenous 5-fluorouracil (5-FU) infusion, weekly adriamycin (ADR) and oral cyclophosphamide (CTX) [FAC-CI] in the treatment of metastatic breast carcinoma (MBC) (abstract 200). Proc. ASCO, 9, 52.
2. GOTTDIENER JS, APPLEBAUM FR, FERRANS VJ, DEISSEROTH A AND ZIEGLER J. (1981). Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch. Intern. Med., 141, 758-763.
3. GREGORY WM, SMITH P, RICHARDS MA, TWELVES CJ, KNIGHT RK AND RUBENS RD. (1993). Chemotherapy of advanced breast cancer: outcome and prognostic factors. Br. J. Cancer, 68, 988-995.
4. HANSEN R, QUEBBEMAN E, BEATTY P, RITCH P, ANDERSON T, JENKINS D, FRICK J AND AUSMAN R. (1987). Continuous 5-fluorouracil infusion in refractory carcinoma of the breast. Breast Cancer Res. Treat., 10, 145-149.
5. HAYWARD JL, CARBONE PP, HEUSON J-C, KUMAOKA S AND SEGALOFF A. (1977). Assessment of response to therapy in advanced breast cancer. Br. J. Cancer, 35, 292-298.
6. HAYWARD JL, CARBONE PP, HEUSON J-C, KUMAOKA S AND SEGALOFF A. (1978). Assessment of response to therapy in advanced breast cancer (an amendment). Br. J. Cancer, 38, 201.
7. HRYNIUK W. (1988). The importance of dose intensity in the outcome of chemotherapy. In Important Advances in Oncology, Hellman S, Devita V and Rosenberg S, (eds) pp. 121-141, Lippincott: Philadelphia.
8. HRYNIUK W AND BUSH H. (1984). The importance of dose intensity in chemotherapy of metastatic breast cancer. J. Clin. Oncol., 2, 1281-1288.
9. JONHS RB, SHPALL EJ, SHOGAN J, AFFRONTI ML, CONIGLIO D, HART L, HALPERIN E, IGLEHART JD, MOORE J, GOCKERMAN J, BAST RC AND PETERS WP. (1990). The Duke AFM Program. Cancer, 66, 431-436.
10. LOKICH JJ, AHLGREEN JD, GULLO JJ, PHILIPS JA AND FRYER JG. (1989). A prospective randomised comparison of continuous infusion fluorouracil with conventional bolus schedule in metastatic colorectal carcinoma: a mid-Atlantic oncology program study. J. Clin. Oncol., 7, 425-432.
11. PRIESTMAN T, BAUM M, JONKS V AND FORBES J. (1978). Treatment and survival in advanced breast cancer. Br. Med. J., 2, 1673-1674.
12. RICHARDS MA, HOPWOOD P, RAMIREZ AJ, TWELVES CJ, FERGUSON F, GREGORY WM, SWINDELL R, SCRIVENER W, MILLER J, HOWELL A AND RUBENS RD. (1992). Doxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life. Eur. J. Cancer, 28A 1023-1028.
13. SMITH IE AND POWLES TJ. (1991). Chemotherapy: General principles. In Medical Management of Breast Cancer, Powles TJ and Smith IE, (eds) pp. 125-132. Martin Dunitz: London.
14. TORTI FM, BRISTOW MR, HOWES AE, ASTON D, STOCKDALE FE, CARTER SK, KOHLER M, BROWN BW AND BILLINGHAM, ME. (1983). Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule: assessment by endomyocardial biopsy. Ann. Int. Med., 99, 745-749.
15. TWELVES CJ, O'REILLY SM, COLEMAN RE, RICHARDS MA AND RUBENS RD. (1989). Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry. Br. J. Cancer, 60, 938-941.
16. TWELVES CJ, DOBBS NA, ALDHOUS M, HARPER PG, RUBENS RD AND RICHARDS MA. (1991). Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer. Cancer Chemother. Pharmacol., 28, 302-307.
17. VALDIVIESO M, BURGESS MA, EWER MS, MACKAY B, WALLACE S, BENJAMIN RS, ALI MK, BODEY GP AND FREIREICH EJ. (1984). Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer: a prospective randomised study. J. Clin. Oncol., 2, 207-214.
18. WEISS A AD MANTHEL R. (1980). Experience with the use of Adriamycin given as a weekly schedule with particular reference to lack of cardiac toxicity. Cancer, 40, 2046-2052.